Vitrakvi Solution
Product Images NDC 71777-392

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 24 technical images submitted to the FDA as part of the official labeling for Vitrakvi (NDC 71777-392). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Loxo Oncology, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Image Of 100 mg Carton Principal Panel (60 capsules)

Image Of 100 mg Carton Principal Panel (60 capsules)
VITRAKVI® is a medication available in capsule form with a strength of 100mg. It contains Larotrectinib, an effective ingredient equivalent to 123mg Larotrectinib sulfate. This medication is meant for oral administration and comes in a bottle containing 60 capsules.*
FDA Label Image

Image Of 25 mg Carton Principal Panel (60 capsules)

Image Of 25 mg Carton Principal Panel (60 capsules)
VITRAKVI® is an oral medication available in the form of capsules containing 25 mg of larotrectinib sulfate. It is a prescription medication utilized for the treatment of certain types of cancer. The package contains 60 capsules for oral use.*
FDA Label Image

Image Of 20 mg/ml Carton Principal Panel (100 mL oral solution)

Image Of 20 mg/ml Carton Principal Panel (100 mL oral solution)
VITRAKVI® is an oral solution medication with 20mg/mL Larotrectinib for oral use, packaged in a 100mL bottle. Each bottle contains Larotrectinib equivalent to 24.6mg/mL tarotrectini sulfate.*
FDA Label Image

Image Of The Chemical Structure Of Vitrakvi (Chem Struct)

Image Of The Chemical Structure Of Vitrakvi (Chem Struct)
FDA Label Image

Image Of Supplies Needed To Take Or Give A Dose Of Vitrakvi Oral Solution (Fig A)

Image Of Supplies Needed To Take Or Give A Dose Of Vitrakvi Oral Solution (Fig A)
This text describes a figure labeled as "Figure A" that includes a bottle, an oral syringe, a 5mL oral syringe, and a bottle adaptor.*
FDA Label Image

Image Of How To Open The Bottle (Fig B)

Image Of How To Open The Bottle (Fig B)
FDA Label Image

Image Of How To Insert The Adaptor Into The Bottle (Fig C)

Image Of How To Insert The Adaptor Into The Bottle (Fig C)
FDA Label Image

Image Of The Oral Syringe And A Close Up Of The Markings In mL (Fig D)

Image Of The Oral Syringe And A Close Up Of The Markings In mL (Fig D)
FDA Label Image

Image Of Of How To Insert The Oral Syringe Into The Bottle (Fig E)

Image Of Of How To Insert The Oral Syringe Into The Bottle (Fig E)
FDA Label Image

Image Of How To Draw Vitrakvi Into The Oral Syringe For Proper Dose (Fig F)

Image Of How To Draw Vitrakvi Into The Oral Syringe For Proper Dose (Fig F)
FDA Label Image

Image Of How To Expell Air Bubbles In The Oral Syringe (Fig G)

Image Of How To Expell Air Bubbles In The Oral Syringe (Fig G)
FDA Label Image

Image Of How To Remove The Oral Syringe From The Bottle (Fig H)

Image Of How To Remove The Oral Syringe From The Bottle (Fig H)
FDA Label Image

Image Of How To Properly Press The Plunger To Deliver The Dose (Fig I)

Image Of How To Properly Press The Plunger To Deliver The Dose (Fig I)
FDA Label Image

Image Of Recapping The Bottle (Fig J)

Image Of Recapping The Bottle (Fig J)
FDA Label Image

Image Of Removing The Plunger From The Barrel Of The Oral Syringe (Fig K)

Image Of Removing The Plunger From The Barrel Of The Oral Syringe (Fig K)
FDA Label Image

Image Of Rinsing The Oral Syringe (plunger And Barrel) (Fig L)

Image Of Rinsing The Oral Syringe (plunger And Barrel) (Fig L)
FDA Label Image

Image Of Re-insertion Of Plunger Into Oral Syringe Barrel (Fig M)

Image Of Re-insertion Of Plunger Into Oral Syringe Barrel (Fig M)
FDA Label Image

Image Of Cleaning Oral Syringe Using Warm Water (Fig N)

Image Of Cleaning Oral Syringe Using Warm Water (Fig N)
FDA Label Image

Image Of Rinsing The Plunger And Barrel Of The Oral Syringe A 2nd Time (Fig O)

Image Of Rinsing The Plunger And Barrel Of The Oral Syringe A 2nd Time (Fig O)
FDA Label Image

Image Of Shaking Excess Water From The Barrel And Plunger (Fig P)

Image Of Shaking Excess Water From The Barrel And Plunger (Fig P)
FDA Label Image

Image Of Where To Write The Date Of When The Bottle Was Opened (Fig Q)

Image Of Where To Write The Date Of When The Bottle Was Opened (Fig Q)
FDA Label Image

Image Of 100 mg Label Principal Panel (60 capsules)

Image Of 100 mg Label Principal Panel (60 capsules)
NDC 71777-391-01 is a medication manufactured by Lovo Oncology Inc. The medication is in capsule form and is called Larotrectinib. Each capsule contains 100mg of Larotrectinib (equivalent to 13mg of Larotrectinib sulfate). The usual dosage information can be found in the prescribing information. The medication should be stored between 20°C to 25°C (68°F to 77°F) and can be kept between 15°C to 30°C (9°F to 86°F) with permission. The medication should be kept away from children.*
FDA Label Image

Image Of 25 mg Label Principal Panel (60 capsules)

Image Of 25 mg Label Principal Panel (60 capsules)
This is a drug information label for VITRAKVI® (Larotrectinib) capsules with the NDC code 71777-390-01. The label mentions the dosage and that it should only be taken with a prescription. The label advises keeping the capsules out of reach of children and storing them at room temperature. The manufacturer of the drug is also provided. The remaining text seems to be an error or not related to the drug information.*
FDA Label Image

Image Of 20 mg/ml Label Principal Panel (100 mL oral solution)

Image Of 20 mg/ml Label Principal Panel (100 mL oral solution)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.